BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced a strategic realignment and the creation of two new highly focused Strategic Business Units – “Unigene Biotechnologies” and “Unigene Therapeutics”. Unigene Biotechnologies will focus on opportunities where the Company can apply its industry-leading Peptelligence™ platform of peptide drug delivery and manufacturing assets, expertise and capabilities to partners’ proprietary development programs. Unigene Therapeutics constitutes Unigene’s own pipeline of novel, proprietary peptide development programs focused on metabolic disease and inflammation.
